Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

81. Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence

Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try

NIHR HTA programme2017

82. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study.

Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. Objective To forecast dementia prevalence with a dynamic modelling approach that integrates calendar trends in dementia incidence with those for mortality and cardiovascular disease. Design Modelling study. Setting General adult population of England and Wales. Participants The English Longitudinal Study of Ageing (ELSA) is a representative panel study with six waves (...) of data across 2002-13. Men and women aged 50 or more years, selected randomly, and their cohabiting partners were recruited to the first wave of ELSA (2002-03). 11392 adults participated (response rate 67%). To maintain representativeness, refreshment participants were recruited to the study at subsequent waves. The total analytical sample constituted 17 906 people. Constant objective criteria based on cognitive and functional impairment were used to ascertain dementia cases at each wave. Main

BMJ2017

83. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public (...) , Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L & Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment 2017; 21(26) Authors' objectives To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community

Health Technology Assessment (HTA) Database.2017

84. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.

Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. Objective To test the hypotheses that physical activity in midlife is not associated with a reduced risk of dementia and that the preclinical phase of dementia is characterised by a decline in physical activity. Design Prospective cohort study with a mean follow-up of 27 years. Setting Civil service departments in London (Whitehall II study). Participants 10 308 participants aged 35-55 (...) years at study inception (1985-88). Exposures included time spent in mild, moderate to vigorous, and total physical activity assessed seven times between 1985 and 2013 and categorised as "recommended" if duration of moderate to vigorous physical activity was 2.5 hours/week or more. Main outcome measures A battery of cognitive tests was administered up to four times from 1997 to 2013, and incident dementia cases (n=329) were identified through linkage to hospital, mental health services

BMJ2017

85. Assistive technology for memory support in dementia.

Assistive technology for memory support in dementia. BACKGROUND: The sustained interest in electronic assistive technology in dementia care has been fuelled by the urgent need to develop useful approaches to help support people with dementia at home. Also the low costs and wide availability of electronic devices make it more feasible to use electronic devices for the benefit of disabled persons. Information Communication Technology (ICT) devices designed to support people with dementia (...) are usually referred to as Assistive Technology (AT) or Electronic Assistive Technology (EAT). By using AT in this review we refer to electronic assistive devices. A range of AT devices has been developed to support people with dementia and their carers to manage their daily activities and to enhance safety, for example electronic pill boxes, picture phones, or mobile tracking devices. Many are commercially available. However, the usefulness and user-friendliness of these devices are often poorly

Cochrane2017

86. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry (...) - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The core outcomes set in disease modification trials in mild to moderate dementia should include cognition markers for all trial participants and a structural magnetic resonance imaging scan for a subset. {{author}} {{($index

NIHR HTA programme2017

87. Atrial fibrillation as a risk factor for cognitive decline and dementia

Atrial fibrillation as a risk factor for cognitive decline and dementia 28460139 2017 05 01 2017 05 01 1522-9645 2017 Apr 29 European heart journal Eur. Heart J. Atrial fibrillation as a risk factor for cognitive decline and dementia. 10.1093/eurheartj/ehx208 To assess whether AF is a risk factor for cognitive dysfunction we used prospective data on AF, repeat cognitive scores, and dementia incidence in adults followed over 45 to 85 years. Data are drawn from the Whitehall II study, N = 10 308 (...) , this relationship was impacted when considering them together (P for trend 0.09). Analysis of incident dementia (N = 274/9302 without AF; N = 50/912 with AF) showed AF was associated with higher risk of dementia in Cox regression adjusted for sociodemographic factors, health behaviours and chronic diseases [hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.37, 2.55]. Multistate models showed AF to increase risk of dementia in those free of stroke (HR: 1.67; 95% CI: 1.17, 2.38) but not those free

EvidenceUpdates2017

88. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia

Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy (...) LS, Barclay T Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS, Barclay T. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia. Rockville: Agency for Healthcare

Health Technology Assessment (HTA) Database.2017

89. The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial

The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial 28350796 2017 03 28 2017 04 07 1549-1676 14 3 2017 Mar PLoS medicine PLoS Med. The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial. e1002269 10.1371/journal.pmed.1002269 Cognitive stimulation (...) therapy (CST) is a well-established group psychosocial intervention for people with dementia. There is evidence that home-based programmes of cognitive stimulation delivered by family caregivers may benefit both the person and the caregiver. However, no previous studies have evaluated caregiver-delivered CST. This study aimed to evaluate the effectiveness of a home-based, caregiver-led individual cognitive stimulation therapy (iCST) program in (i) improving cognition and quality of life (QoL) for the

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

90. Simulated presence therapy for dementia.

Simulated presence therapy for dementia. BACKGROUND: Dementia is a common and serious neuropsychiatric syndrome, characterised by progressive cognitive and functional decline. The majority of people with dementia develop behavioural disturbances, also known as behavioural and psychological symptoms of dementia (BPSD). Several non-pharmacological interventions have been evaluated to treat BPSD in people with dementia. Simulated presence therapy (SPT), an intervention that uses video or audiotape (...) recordings of family members played to the person with dementia, is a possible approach to treat BPSD. OBJECTIVES: To assess the effects of SPT on behavioural and psychological symptoms and quality of life in people with dementia. SEARCH METHODS: We searched ALOIS (the Specialised Register of the Cochrane Dementia and Cognitive Improvement Group), CENTRAL (The Cochrane Library) (9 February 2016), MEDLINE Ovid SP (1946 to 6 January 2017), Embase Ovid SP (1972 to 6 January 2017), PsycINFO Ovid SP (1806

Cochrane2017

91. Vitamin E for Alzheimer's dementia and mild cognitive impairment.

Vitamin E for Alzheimer's dementia and mild cognitive impairment. BACKGROUND: Vitamin E occurs naturally in the diet. It has several biological activities, including functioning as an antioxidant to scavenge toxic free radicals. Evidence that free radicals may contribute to the pathological processes behind cognitive impairment has led to interest in the use of vitamin E supplements to treat mild cognitive impairment (MCI) and Alzheimer's disease (AD). This is an update of a Cochrane Review (...) first published in 2000, and previously updated in 2006 and 2012. OBJECTIVES: To assess the efficacy of vitamin E in the treatment of MCI and dementia due to AD. SEARCH METHODS: We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, LILACS as well as many trials databases and grey literature sources on 22 April 2016 using the terms: "Vitamin E", vitamin-E, alpha-tocopherol. SELECTION CRITERIA: We

Cochrane2017

92. Posttraumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans

Posttraumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans 28306156 2017 03 17 2017 03 17 1532-5415 2017 Mar 17 Journal of the American Geriatrics Society J Am Geriatr Soc Posttraumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans. 10.1111/jgs.14837 To examine the risk of dementia associated with posttraumatic stress disorder (PTSD) and the contribution of antipsychotic use to this risk. Retrospective cohort study SETTING: Australia. Administrative (...) claims data from the Australian Government Department of Veterans' Affairs were used. Male Vietnam veterans aged 55 to 65 at baseline (2001-02) with no preexisting dementia diagnosis (N = 15,612). The association between PTSD and dementia was assessed over 12 years of follow-up. Dementia was identified as a hospital diagnosis, dementia record in service disability data, or dispensing of medicines for dementia. Cox-proportional hazards models were used, with age as the time-scale. Results were

EvidenceUpdates2017

93. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: Research suggests that measurable change in cerebrospinal fluid (CSF) biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this review, we aimed to assess the ability of CSF tau biomarkers (t-tau and p-tau) and the CSF tau (t-tau or p-tau)/ABeta ratio to enable the detection of Alzheimer's disease (...) pathology in patients with mild cognitive impairment (MCI). These biomarkers have been proposed as important in new criteria for Alzheimer's disease dementia that incorporate biomarker abnormalities. OBJECTIVES: To determine the diagnostic accuracy of 1) CSF t-tau, 2) CSF p-tau, 3) the CSF t-tau/ABeta ratio and 4) the CSF p-tau/ABeta ratio index tests for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease dementia or other forms of dementia at follow-up. SEARCH

Cochrane2017

94. A feasibility randomised controlled trial of the DECIDE intervention: dementia carers making informed decisions.

A feasibility randomised controlled trial of the DECIDE intervention: dementia carers making informed decisions. 28243460 2017 02 28 2017 03 02 3 1 2017 Jan BJPsych open BJPsych Open A feasibility randomised controlled trial of the DECIDE intervention: dementia carers making informed decisions. 12-14 10.1192/bjpo.bp.116.003509 Family carers report high levels of decisional conflict when deciding whether their relative with dementia can continue to be cared for in their own home. We tested

BJPsych open2017 Full Text: Link to full Text with Trip Pro

95. Dance movement therapy for dementia.

Dance movement therapy for dementia. BACKGROUND: Dementia is a collective name for different degenerative brain syndromes which, according to Alzheimer's Disease International, affects approximately 35.6 million people worldwide. The latest NICE guideline for dementia highlights the value of diverse treatment options for the different stages and symptoms of dementia including non-pharmacological treatments. Relevant literature also argues for the value of interventions that acknowledge (...) the complexity of the condition and address the person as a whole, including their physical, emotional, social and cognitive processes. At the same time, there is growing literature that highlights the capacity of the arts and embodied practices to address this complexity. Dance movement therapy is an embodied psychological intervention that can address complexity and thus, may be useful for people with dementia, but its effectiveness remains unclear. OBJECTIVES: To assess the effects of dance movement

Cochrane2017

96. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer

Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer 27870566 2016 11 21 2017 02 10 1527-7755 35 2 2017 Jan 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. 201-207 Purpose Recent observational studies have associated the use of androgen deprivation therapy (ADT) with an increased risk of dementia and Alzheimer's (...) disease, but these studies had limitations. The objective of this study was to determine whether the use of ADT is associated with an increased risk of dementia, including Alzheimer's disease, in patients with prostate cancer. Patients and Methods Using the United Kingdom's Clinical Practice Research Datalink, we assembled a cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer between April 1, 1988 and April 30, 2015, and observed them until April 30, 2016. Time-dependent Cox

EvidenceUpdates2017

97. Support at Home: Interventions to Enhance Life in Dementia (SHIELD) evidence, development and evaluation of complex interventions

Support at Home: Interventions to Enhance Life in Dementia (SHIELD) evidence, development and evaluation of complex interventions Support at Home: Interventions to Enhance Life in Dementia (SHIELD) evidence, development and evaluation of complex interventions Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website (...) search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The SHIELD programme shows that psychosocial interventions can improve quality of life for people with dementia (and is likely to be cost-effective) {{author}} {{($index , , , , , , , , , , , , , , & . Martin Orrell, 1 ,* Juanita Hoe, 1 Georgina Charlesworth, 1 Ian Russell, 2 David Challis, 3 Esme Moniz-Cook, 4 Martin Knapp, 5 Bob Woods, 6 Zoe Hoare, 6 Elisa

NIHR HTA programme2017

98. Mobility Beds for Patients with Dementia: Clinical Effectiveness and Cost-Effectiveness

Mobility Beds for Patients with Dementia: Clinical Effectiveness and Cost-Effectiveness Mobility Beds for Patients with Dementia: Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Mobility Beds for Patients with Dementia: Clinical Effectiveness and Cost-Effectiveness Mobility Beds for Patients with Dementia: Clinical Effectiveness and Cost-Effectiveness Published on: January 25, 2017 Project Number: RB1058-000 Product Line: Research Type: Devices and Systems (...) Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of mobility beds or mattresses for patients with dementia? What is the cost-effectiveness of mobility beds or mattresses for patients with dementia? Key Message No literature was identified regarding the clinical or cost-effectiveness of mobility beds or mattresses for patients with dementia. Tags dementia, geriatrics, beds, delirium, delirium, dementia, amnestic, cognitive disorders, Bed, beds, mattress

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

99. Technologies to Support Community-Dwelling Persons With Dementia: A Position Paper on Issues Regarding Development, Usability, Effectiveness and Cost-Effectiveness, Deployment, and Ethics

Technologies to Support Community-Dwelling Persons With Dementia: A Position Paper on Issues Regarding Development, Usability, Effectiveness and Cost-Effectiveness, Deployment, and Ethics 28582262 2018 11 13 2369-2529 4 1 2017 Jan 16 JMIR rehabilitation and assistive technologies JMIR Rehabil Assist Technol Technologies to Support Community-Dwelling Persons With Dementia: A Position Paper on Issues Regarding Development, Usability, Effectiveness and Cost-Effectiveness, Deployment, and Ethics (...) . e1 10.2196/rehab.6376 With the expected increase in the numbers of persons with dementia, providing timely, adequate, and affordable care and support is challenging. Assistive and health technologies may be a valuable contribution in dementia care, but new challenges may emerge. The aim of our study was to review the state of the art of technologies for persons with dementia regarding issues on development, usability, effectiveness and cost-effectiveness, deployment, and ethics in 3 fields

JMIR rehabilitation and assistive technologies2017 Full Text: Link to full Text with Trip Pro

100. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.

Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. BACKGROUND: Emerging evidence suggests that living near major roads might adversely affect cognition. However, little is known about its relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis. We aimed to investigate the association between residential proximity to major roadways and the incidence of these three neurological (...) diseases in Ontario, Canada. METHODS: In this population-based cohort study, we assembled two population-based cohorts including all adults aged 20-50 years (about 4·4 million; multiple sclerosis cohort) and all adults aged 55-85 years (about 2·2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Canada on April 1, 2001. Eligible patients were free of these neurological diseases, Ontario residents for 5 years or longer, and Canadian-born. We ascertained the individual's proximity

Lancet2017